Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Cryo Cell International (CCEL) over the last 16 years, with Q3 2025 value amounting to $36780.0.

  • Cryo Cell International's Share-based Compensation fell 7479.8% to $36780.0 in Q3 2025 from the same period last year, while for Aug 2025 it was $523865.0, marking a year-over-year decrease of 3505.32%. This contributed to the annual value of $781128.0 for FY2024, which is 439.07% down from last year.
  • According to the latest figures from Q3 2025, Cryo Cell International's Share-based Compensation is $36780.0, which was down 7479.8% from $40000.0 recorded in Q2 2025.
  • In the past 5 years, Cryo Cell International's Share-based Compensation ranged from a high of $313174.0 in Q1 2023 and a low of $32000.0 during Q1 2022
  • Its 5-year average for Share-based Compensation is $143985.8, with a median of $149693.0 in 2024.
  • As far as peak fluctuations go, Cryo Cell International's Share-based Compensation surged by 87866.88% in 2023, and later plummeted by 7752.81% in 2025.
  • Cryo Cell International's Share-based Compensation (Quarter) stood at $68000.0 in 2021, then skyrocketed by 121.92% to $150904.0 in 2022, then rose by 16.17% to $175310.0 in 2023, then fell by 14.61% to $149693.0 in 2024, then crashed by 75.43% to $36780.0 in 2025.
  • Its Share-based Compensation was $36780.0 in Q3 2025, compared to $40000.0 in Q2 2025 and $297392.0 in Q1 2025.